Veru (VERU) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VERU Veru Inc VERU
27 GF Score
Price $2.44
! 3 Warning Signs
View Full Analysis

What is Veru Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Veru  (NAS:VERU) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Veru Cyclically Adjusted PB Ratio Related Terms


Veru Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Veru's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru Cyclically Adjusted PB Ratio Chart

Veru Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.10 10.18 0.68 0.79 0.44

Veru Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.39 0.23 0.24 0.36

VERU vs TVGN, GRCE, MGX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Veru's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veru Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veru's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Veru's Cyclically Adjusted PB Ratio falls into.


VERU
27GF Score
Veru Inc VERU
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veru Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Veru's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Veru's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.664/333.9520*333.9520
=1.664

Current CPI (Jun. 2026) = 333.9520.

Veru Quarterly Data

Book Value per Share CPI Adj_Book
201609 11.665 241.428 16.135
201612 11.245 241.432 15.554
201703 10.701 243.801 14.658
201706 10.471 244.955 14.275
201709 9.106 246.819 12.321
201712 8.363 246.524 11.329
201803 7.724 249.554 10.336
201806 6.552 251.989 8.683
201809 5.333 252.439 7.055
201812 5.890 251.233 7.829
201903 5.343 254.202 7.019
201906 5.359 256.143 6.987
201909 4.971 256.759 6.466
201912 4.558 256.974 5.923
202003 4.736 258.115 6.127
202006 5.909 257.797 7.655
202009 4.310 260.280 5.530
202012 6.779 260.474 8.691
202103 19.514 264.877 24.603
202106 19.407 271.696 23.854
202109 19.044 274.310 23.185
202112 18.489 278.802 22.146
202203 16.986 287.504 19.730
202206 14.585 296.311 16.438
202209 10.013 296.808 11.266
202212 6.090 296.797 6.852
202303 2.024 301.836 2.239
202306 2.400 305.109 2.627
202309 2.144 307.789 2.326
202312 3.525 306.746 3.838
202403 3.088 312.332 3.302
202406 2.570 314.175 2.732
202409 2.208 315.301 2.339
202412 1.819 315.605 1.925
202503 1.436 319.799 1.500
202506 1.047 322.561 1.084
202509 1.251 324.800 1.286
202512 2.313 324.054 2.384
202603 2.167 330.213 2.192
202606 1.664 333.952 1.664

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Veru Business Description

Address 2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
27GF Score

Get the complete analysis for VERU

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.44
Price